AbbVie makes neuro drug connection with $130M Syndesi Therapeutics acquisition March 2, 2022 Auto Bot AbbVie, alzheimer's disease, BioPharma, biopharma nl, Clinical Trials, deals, neuroscience, North Chicago, Pharma, UCB 0 AbbVie has acquired Syndesi Therapeutics, an early clinical neuroscience startup developing drugs that have potential applications in a range of cognitive disorders. Syndesi is based on research from Belgian pharmaceutical company UCB.